Royal College of Surgeons in Ireland
Manama, Bahrain
NCT Number: NCT06652867
The study aims to obtain a panel of biomarkers from hypoglycemic diabetic patients with either type 1 or type 2 diabetics and from control patients with type 1 or type 2 diabetes who didn't have hypoglycemia in the last 72 hours.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Observational
Manama, Bahrain
Primary endpoint is establishing a panel of biomarkers from 100 hypoglycemic diabetic patients with type 1 or type 2 Diabetes during the incidence of hypoglycemia by taking a single blood sample to be analyzed for HbA1c, LDL, HDL, Triglycerides, CRP, CBC and biochemical analysis including liver and kidney function tests. In addition to 5 ml serum sample to be centrifuged and stored in RCSI lab.
Inpatient hypoglycemic patients may also be included in group of hypoglycemia and will be required to have a serial of blood samples taken to be analyzed on the 1st hour, 2nd hour, 3rd hour and 4th hour after the hypoglycemic event.
Secondary endpoint involves recruitment of 100 control Diabetic patients with type 1 or type 2 Diabetes to establish a panel of biomarkers by obtaining a blood sample for the HbA1c, LDL, HDL, Triglycerides, CRP, CBC and biochemical analysis including liver and kidney function tests to include 50 subjects fasting overnight and the other 50 subjects to be non-fasting but without having hypoglycemia at the time of recruitment or in the last 72 hours.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for diabetes subjects with hypoglycemia
Inclusion criteria
for diabetes subjects without hypoglycemia:
Exclusion criteria
Exclusion criteria
for diabetes subjects with hypoglycemia
Exclusion criteria
for diabetes subjects without hypoglycemia
Time frame: 1 day from time of presentation
a panel of biomarkers is measured from a blood test taken during the incidence of hypoglycemia from type 1 or type 2 Diabetic subject.
Time frame: 3 days from time of presentation
a panel of biomarkers is measured from a blood test taken from Diabetic subjects (type 1 or type 2) without having hypoglycemia.
Time frame: 1 day from time of presentation
Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients
Time frame: 1 day from time of presentation
Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients
Time frame: 1 day from time of presentation
Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients
Time frame: 1 day from time of presentation
Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients
Time frame: 1 day from time of presentation
Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients
Time frame: 1 day from time of presentation
Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients
Time frame: 1 day from time of presentation
Measured from a blood test taken from Diabetic subjects (type 1 or type 2) control group and hypoglycemic patients
Royal College of Surgeons in Ireland - Medical University of Bahrain
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05597605
Acid-Base Imbalance, Acidosis
Antwerp, Belgium
View Trial DetailsNCT04304963
Autoimmune Diseases, Diabetes Mellitus
London, United Kingdom
View Trial DetailsNCT03976271
Autoimmune Diseases, Diabetes Mellitus
Hillerød, Nordsjaelland, Denmark
View Trial DetailsNCT04219514
Autoimmune Diseases, Diabetes Mellitus
New York, United States
View Trial Details